Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 6/20 | 0.66 |
| ▸ | CDK1 | P06493 | 8/20 | 0.65 |
| ▸ | MTOR | P42345 | 6/20 | 0.65 |
| ▸ | CDK2 | P24941 | 6/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.65 |
| ▸ | SMG1 | Q96Q15 | 5/20 | 0.65 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.64 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.64 |
| ▸ | CDK9 | P50750 | 4/20 | 0.63 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.63 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.63 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.63 |
| ▸ | CDK7 | P50613 | 2/20 | 0.63 |
| ▸ | CCNH | P51946 | 2/20 | 0.63 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.63 |
| ▸ | GSK3B | P49841 | 2/20 | 0.59 |
| ▸ | DKK1 | O94907 | 1/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7524252 | 0.87 | CDK1 (0.69) | IKBKBCDK1MTORCDK2PIK3CA | |
| SCHEMBL3753567 | 0.84 | IKBKB (0.68) | IKBKBMAPK8MAPK10GSK3BDKK1 | |
| SCHEMBL7471938 | 0.84 | ABL1 (0.70) | IKBKBCDK1MTORCDK2PIK3CA | |
| SCHEMBL3760561 | 0.84 | MAPK8 (0.64) | IKBKBCDK1MTORCDK2PIK3CA | |
| SCHEMBL6752979 | 0.83 | CAMK2D (0.67) | IKBKBCDK1MTORCDK2PIK3CA | |
| SCHEMBL30847388 | 0.82 | CDK1 (0.60) | IKBKBCDK1MTORCDK2PIK3CA | |
| SCHEMBL27152320 | 0.82 | CDK1 (0.60) | IKBKBCDK1MTORCDK2PIK3CA | |
| SCHEMBL3521890 | 0.81 | CDK1 (0.62) | IKBKBCDK1MTORCDK2PIK3CA | |
| SCHEMBL14253959 | 0.81 | IKBKB (0.67) | IKBKBCDK1MTORCDK2PIK3CA | |
| SCHEMBL3520990 | 0.81 | CDK1 (0.66) | IKBKBCDK1MTORCDK2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | claimed |
| US-20090048282-A1 | PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-19 | — | — | US | claimed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | claimed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090048282-A1 | PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-19 | — | — | US | disclosed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048282-A1 | PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | IKBKB 1593/4885CDK1 493/4885MTOR 744/4885 |
| US-20060079543-A1 | Anilino-pyrimidine analogs | DPYD, TYMP, ADORA3 | IKBKB 3246/4885CDK1 43/4885MTOR 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.